Table 1. Examples of oocyte maturation defect phenotypes.
Protocol | Phenotype | References | Model parameters | Figures |
ablated | MI-entry delay | [8] | Fig. 5A | |
ablated | MII-entry failure | [4] | Fig. 5A | |
ablated | MI-entry delay | [5], [8] | Fig. 5B | |
ablated | Oscillations | [7] | Fig. 5B | |
ablated | MI-entry failure | [8] | , | Not shown |
ablated | MI-entry delay/failure | [22], [40] | Fig. 5C | |
U0126( inhibitor) | MI/MII failure | [5], [6] | Fig. 5D | |
overexpressed | MI arrest | [11] | Fig. 5E | |
ablated | MII-entry failure | [10], [20] | Fig. 5F |
Pharmacological or antisense treatments impacting the activity of several specific proteins lead to various sorts of maturation defect phenotypes as reported in the literature. B-type cyclin is abbreviated as Cyc. Changing specific parameters of the model allows to simulate these phenotypes, which is also shown in Fig. 5.